Sugi Predict

Sugi Predict / Compounds / SCHEMBL195145

SCHEMBL195145

SCHEMBL195145

O=C(O)c1cc([N+](=O)[O-])ccc1F

nearest known ligand 0.59

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 5/20 0.59
▸ TDP1 Q9NUW8 2/20 0.59
▸ CYP3A4 P08684 1/20 0.59
▸ ALOX15 P16050 1/20 0.59
▸ MAPT P10636 3/20 0.58
▸ HIF1A Q16665 1/20 0.56
▸ TP53 P04637 2/20 0.54
▸ HTT P42858 2/20 0.54
▸ CTSV O60911 1/20 0.54
▸ CTSL P07711 1/20 0.54
▸ KMT2A Q03164 3/20 0.53
▸ SMN1; SMN2 Q16637 1/20 0.53
▸ MEN1 O00255 2/20 0.50
▸ GAA P10253 1/20 0.50
▸ LMNA P02545 1/20 0.50
▸ MAOA P21397 1/20 0.49
▸ MAOB P27338 1/20 0.49
▸ MYC P01106 1/20 0.48
▸ MAX P61244 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1654660 1.00 ALDH1A1 (0.59) ALDH1A1TDP1CYP3A4ALOX15MAPT
SCHEMBL887048 0.98 ALDH1A1 (0.57) ALDH1A1TDP1CYP3A4ALOX15MAPT
Hydrochloric Acid SCHEMBL1671414 0.98 ALDH1A1 (0.57) ALDH1A1TDP1CYP3A4ALOX15MAPT
SCHEMBL29099706 0.91 ALDH1A1 (0.54) ALDH1A1TDP1CYP3A4ALOX15MAPT
SCHEMBL77925 0.85 ALDH1A1 (0.64) ALDH1A1TDP1CYP3A4ALOX15MAPT
SCHEMBL25837924 0.85 ALDH1A1 (0.64) ALDH1A1TDP1CYP3A4ALOX15MAPT
SCHEMBL284069 0.84 ALDH1A1 (0.55) ALDH1A1TDP1CYP3A4ALOX15MAPT
SCHEMBL4485751 0.84 KMT2A (0.60) ALDH1A1TDP1CYP3A4ALOX15HIF1A
SCHEMBL13844206 0.84 KMT2A (0.60) ALDH1A1TDP1CYP3A4ALOX15HIF1A
Silver SCHEMBL887047 0.84 ALDH1A1 (0.55) ALDH1A1TDP1CYP3A4ALOX15MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1059 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4661890-A1 PTP1B/TC-PTP DUAL INHIBITORS AND PROTEIN DEGRADERS Purdue Research Foundation (US) 2025-12-17 — — EP claimed
US-12281179-B2 Solution phase synthesis of β-turn peptidomimetic cyclic salts MIMETOGEN PHARMACEUTICALS, INC. (CA) 2025-04-22 — — US claimed
CN-119569678-A Thionitrous near-infrared bioluminescence probe and preparation method and application thereof 徐州医科大学 2025-03-07 — — CN claimed
CN-119390650-A Preparation method of diamine monomer containing acridone unit 东华大学 2025-02-07 — — CN claimed
CN-118812209-A Preparation method of polyvinyl alcohol emulsion modified cement paste generated in situ 海南大学 2024-10-22 — — CN claimed
CN-118621569-A Polyvinyl alcohol fiber surface acetalation modification method 海南大学 2024-09-10 — — CN claimed
WO-2024167565-A1 PTP1B/TC-PTP DUAL INHIBITORS AND PROTEIN DEGRADERS PURDUE RESEARCH FOUNDATION (US) 2024-08-15 — — WO claimed
CN-116283831-B P-nitrobenzene derivative and preparation method and application thereof 中国医学科学院医药生物技术研究所 2024-07-23 — — CN claimed
CN-115974812-B Fluorescent probe for nondestructive monitoring of fish freshness and preparation method and application thereof 渤海大学 2024-03-08 — — CN claimed
CN-117567346-A Bismaleimide and preparation method thereof, and method for preparing aviation heat-resistant die plate 重庆渝启欣科技发展有限公司 2024-02-20 — — CN claimed
WO-2010118241-A2 INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (US) 2010-10-14 — — WO claimed
US-7732625-B2 Colorant compounds XEROX CORPORATION (US) 2010-06-08 — — US claimed
US-7311767-B2 Forming a salt of a liquid phase change ink carrier of stearyl stearamide, an amine substituted Xanthene, acridine, anthracene or thioxanthene chromogen, and a metal salt capable of forming a compound with two chromogens XEROX CORPORATION (US) 2007-12-25 — — US claimed
US-7033424-B2 Phase change inks XEROX CORPORATION (US) 2006-04-25 — — US claimed
US-20060021546-A1 Processes for preparing phase change inks XEROX CORPORATION 2006-02-02 — — US claimed
US-20060020141-A1 Metallized dye XEROX CORPORATION 2006-01-26 — — US claimed
US-20060016369-A1 PHASE CHANGE INKS XEROX CORPORATION 2006-01-26 — — US claimed
US-6946025-B2 Process for preparing tetra-amide compounds XEROX CORPORATION (US) 2005-09-20 — — US claimed
EP-1377589-B1 OXAZOLYL-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS PHARMACIA ITALIA SPA (IT) 2005-09-07 — — EP claimed
US-20050090690-A1 Process for preparing tetra-amide compounds XEROX CORPORATION 2005-04-28 — — US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060020141-A1 Metallized dye CDYL, CDY1; CDY1B, CDYL2 ALDH1A1 1569/4885TDP1 3338/4885CYP3A4 797/4885
US-20050090690-A1 Process for preparing tetra-amide compounds TAF9, TAF5, TAF1 ALDH1A1 1723/4885TDP1 1182/4885CYP3A4 548/4885
US-12281179-B2 Solution phase synthesis of β-turn peptidomimetic cyclic salts PNISR, CGAS, NGLY1 ALDH1A1 4799/4885TDP1 1201/4885CYP3A4 3800/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.